Shares of Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 6, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.

Allspring Global Investments Holdings LLC trimmed its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 8.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,995,596 shares of the medical research company's stock after selling 182,345 shares during

Contravisory Investment Management Inc. bought a new position in Charles River Laboratories International, Inc. (NYSE: CRL) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 6,129 shares of the medical research company's stock, valued at approximately $1,223,000. A

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Algert Global LLC increased its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 54.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 112,870 shares of the medical research company's stock after purchasing an additional 39,586 shares during

Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Cresset Asset Management LLC boosted its position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 57.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,703 shares of the medical research company's stock after purchasing an additional 3,173 shares during

Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at TD Cowen and Barclays Conferences.